The TRINITY study: Twitter discussion from a respirology journal club

Affiliations

¹ University of Toronto, Toronto, ON, Canada.
² University of Toronto, Toronto, ON, Canada; St Michael's Hospital, Toronto, ON, Canada. Electronic address: ananda@smh.ca.
³ University of Toronto, Toronto, ON, Canada; Toronto Western Hospital, Toronto, ON, Canada.

Comment

Melissa Brijbassi et al. Lancet Respir Med. 2017 Jul.

. 2017 Jul;5(7):e25.

doi: 10.1016/S2213-2600(17)30231-X.

¹ University of Toronto, Toronto, ON, Canada.
² University of Toronto, Toronto, ON, Canada; St Michael's Hospital, Toronto, ON, Canada. Electronic address: ananda@smh.ca.
³ University of Toronto, Toronto, ON, Canada; Toronto Western Hospital, Toronto, ON, Canada.

No abstract available

Comment in

The TRINITY study: Twitter discussion from a respirology journal club - Authors' reply.
Vestbo J; TRINITY investigators. Vestbo J, et al. Lancet Respir Med. 2017 Jul;5(7):e26. doi: 10.1016/S2213-2600(17)30230-8. Lancet Respir Med. 2017. PMID: 28664866 No abstract available.

Single inhaler extrafine triple therapy versus long-acting muscarinic antagonist therapy for chronic obstructive pulmonary disease (TRINITY): a double-blind, parallel group, randomised controlled trial.
Vestbo J, Papi A, Corradi M, Blazhko V, Montagna I, Francisco C, Cohuet G, Vezzoli S, Scuri M, Singh D. Vestbo J, et al. Lancet. 2017 May 13;389(10082):1919-1929. doi: 10.1016/S0140-6736(17)30188-5. Epub 2017 Apr 3. Lancet. 2017. PMID: 28385353 Clinical Trial.